01 October 2004
Chemopreventive effect of M2000, a new anti-inflammatory agent
Abbas Mirshafiey, Mohammad Reza Khorramizadeh, Farshid Saadat, Bernd H.A. RehmMed Sci Monit 2004; 10(10): PI105-109 :: ID: 11789
Abstract
Background:An emerging body of literature has recently defined a reduced risk of cancer following the use of nonsteroidal anti-inflammatory drugs (NSAIDs), which are generally able to exert an apoptotic property and inhibitory effects on the activity and/or expression of matrix metalloproteinases (MMPs). This study was undertaken to explore the role of a newly designed NSAID, M2000 (C[sub]6[/sub]H[sub]10[/sub]O[sub]7[/sub]), as an anti-inflammatory drug in chemoprevention therapy under in vitro conditions.Material/Methods: The influence of M2000 on a fibrosarcoma cell line (WEHI-164) was investigated using an in vitro cytotoxicity assay, terminal deoxyribonucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay to assess apoptosis, and gelatin zymography for evaluating the activity of matrix metalloproteinase 2 (MMP-2).Results: Cytotoxicity analysis of M2000 showed a much higher tolerability than the other tested drugs (diclofenac, piroxicam, and dexamethasone) in that it showed no cytotoxic effect compared with them. The dose-dependent inhibitory effect of M2000 at concentrations of 20, 40, 80, and 200 µg/ml was significantly greater than that of dexamethasone and of piroxicam at a concentration of 200 µg/ml, whereas the inhibitory activity of M2000 paralleled diclofenac at doses of 10, 20, 40, and 200 µg/ml. Moreover, the apoptotic efficacy of M2000 was similar to that of dexamethasone.Conclusions: Based on our data, the induction of apoptosis together with MMP-2 inhibition could be indicative of a chemopreventive property of M2000. Thus this novel NSAID might be considered as a chemopreventive drug in the potential prevention and treatment of cancer and in inhibition of the angiopathogenic process.
Keywords: Anti-Inflammatory Agents - pharmacology, Antineoplastic Agents - pharmacology, Fibrosarcoma - enzymology, Fibrosarcoma - pathology, Fibrosarcoma - prevention & control, Hydrocarbons - pharmacology, Matrix Metalloproteinase 2 - metabolism, Mice, Anti-Inflammatory Agents - pharmacology, Antineoplastic Agents - pharmacology, Fibrosarcoma - prevention & control, Hydrocarbons - pharmacology, Matrix Metalloproteinase 2 - metabolism
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952